Resveratrol supplementation improves inflammatory biomarkers in patients with nonalcoholic fatty liver disease

Faghihzadeh, Forouzan; Adibi, Peyman; Rafiei, Rahmatollah; Hekmatdoost, Azita

doi:10.1016/j.nutres.2014.09.005

Cited by 274 publications

(224 citation statements)

References 34 publications

Supporting

Mentioning

215

Contrasting

Unclassified

Order By: Relevance

“…In two trials resveratrol was administrated at a dose of 300mg and 500mg for three months [11,19], in one study at a dose of 1500mg daily for six months [18], and in one study a dose of 3000mg daily was utilized and followed up the patients were followed-up only for two months [10]. One trial recommended a healthy diet and regular exercise for its participants [19], while the remaining trials asked their patients to maintain usual lifestyle and habitual dietary intake. Summary of included studies and their main results are shown in Table I and baseline characteristics of their populations are shown in Table II.…”

Section: Characteristics Of Included Studiesmentioning

confidence: 99%

See 1 more Smart Citation

Resveratrol Supplementation in Patients with Non-Alcoholic Fatty Liver Disease: Systematic Review and Meta-analysis

Elgebaly¹,

Radwan²,

AboElnas³

et al. 2017

JGLD

View full text Add to dashboard Cite

Background: Resveratrol is a potential treatment option for management of non-alcoholic fatty liver disease (NAFLD) due to its anti-inflammatory, antioxidant properties, and calorie restriction-like effects. We aimed to synthesise evidence from published randomized clinical trials (RCTs) about the efficacy of resveratrol in the management of NAFLD.Methods: A computer literature search of PubMed, Scopus, Web of Science, and Cochrane Central was conducted using relevant keywords. Records were screened for eligible studies and data were extracted and synthesized using Review Manager Version 5.3 for windows. Subgroup analysis and sensitivity analysis were conducted.Results: Four RCTs (n=158 patients) were included in the final analysis. The overall effect estimates did not favor resveratrol group in terms of: serum ALT (MD -2.89, 95%CI [-15.66, 9.88], p=0.66), serum AST (MD -3.59, 95%CI [-13.82, 6.63], p=0.49), weight (MD -0.18, 95%CI [-0.92, 0.55], p=0.63), BMI (MD -0.10, 95 %CI [-0.43, 0.24], p=0.57), blood glucose level (MD -0.27, 95%CI [-0.55, 0.01], p=0.05), insulin level (MD -0.12, 95%CI [-0.69, 0.46], p=0.69), triglyceride level (MD 0.04, 95%CI [-0.45, 0.53], p=0.87), and LDL level (MD 0.21, 95%CI [-0.41, 0.83], p=0.51). Pooled studies were heterogeneous.Conclusion: Current evidence is insufficient to support the efficacy of resveratrol in the management of NAFLD. Resveratrol does not attenuate the degree of liver fibrosis or show a significant decrease in any of its parameters.Abbreviations: ALT: Alanine aminotransferase; AMPK: AMP-activated protein kinase; AST: Aspartate aminotransferase; BMI: Body mass index; CK-18: Cytokeratin-18; CRP: C-reactive protein; HC: Head circumference; HDL: High density lipoprotein; IL-6: Interleukin-6; LDL: Low density lipoprotein; MD: Mean difference; NAFLD: Non-alcoholic fatty liver disease; NASH: Non-alcoholic steatohepatitis; RCT: Randomized Controlled Trial; RR: Relative risk; SIRT1: Silent information regulation 2 homologue 1; TNF-α: Tumor necrosis factor α; WC: Waist circumference; WHR: Waist hip ratio.

show abstract

Section: Characteristics Of Included Studiesmentioning

confidence: 99%

“…Only one study assessed the effect of resveratrol on liver histology and degree of fibrosis [19]. The mean change in the degree of fibrosis was -0.84 in the resveratrol group vs. 0.06 in the placebo group.…”

Section: Liver Histology and Degree Of Fibrosismentioning

confidence: 99%

Resveratrol Supplementation in Patients with Non-Alcoholic Fatty Liver Disease: Systematic Review and Meta-analysis

Elgebaly¹,

Radwan²,

AboElnas³

et al. 2017

JGLD

View full text Add to dashboard Cite

show abstract

“…Several recent studies reported that polyphenol compounds attenuate inflammatory markers and hepatic steatosis grade in patients with NAFLD (142)(143)(144)(145). Some of these act through the amelioration of insulin resistance, whereas some act through the modulation of the gut microbiome (146,147).…”

Section: Introductionmentioning

confidence: 99%

Nonalcoholic Fatty Liver Disease, the Gut Microbiome, and Diet

Mokhtari

Gibson

Hekmatdoost

2017

Advances in Nutrition

Self Cite

132

View full text Add to dashboard Cite

Nonalcoholic fatty liver disease (NAFLD) is the most common liver disorder in the world, yet the pathogenesis of the disease is not well elucidated. Due to the close anatomic and functional association between the intestinal lumen and the liver through the portal system, it is speculated that the gut microbiome may play a pivotal role in the pathogenesis of NAFLD. Furthermore, diet, which can modulate the gut microbiome and several metabolic pathways involved in NAFLD development, shows a potential tripartite relation between the gut, diet, and the liver. In this review, we summarize the current evidence that supports the association between NAFLD, the gut microbiome, and the role of diet. Adv Nutr 2017;8:240-52.

show abstract

“…In a recent study, it was found that mice fed with a methionine–choline‐deficient diet and receive daily intra‐gastric administration of RSV (100 or 250 mg/kg body weight) resulted in reduction of hepatic steatosis and inflammation, while the curative effects of RSV were not seen in the improvement of steatohepatitis (Heebøll et al., 2015). In another study, the findings have shown that daily consumption of RSV with a dose of 500 mg for 12 weeks improved nonalcoholic fatty liver disease in a clinical trial (Faghihzadeh, Adibi, Rafiei, & Hekmatdoost, 2014). The bases for the beneficial effects of RSV are unclear yet.…”

Section: Resveratrol and Diseasesmentioning

confidence: 97%

Resveratrol: A miraculous natural compound for diseases treatment

Koushki

Amiri-Dashatan

Ahmadi

et al. 2018

Food Science & Nutrition

165

View full text Add to dashboard Cite

Resveratrol (3, 5, 4′‐trihydroxystilbene) is a nonflavonoid polyphenol that naturally occurs as phytoalexin. It is produced by plant sources such as grapes, apples, blueberries, plums, and peanut. This compound has critical roles in human health and is well known for its diverse biological activities such as antioxidant and anti‐inflammatory properties. Nowadays, due to rising incidence of different diseases such as cancer and diabetes, efforts to find novel and effective disease‐protective agents have led to the identification of plant‐derived compounds such as resveratrol. Furthermore, several in vitro and in vivo studies have revealed the effectiveness of resveratrol in various diseases such as diabetes mellitus, cardiovascular disease, metabolic syndrome, obesity, inflammatory, neurodegenerative, and age‐related diseases. This review presents an overview of currently available studies on preventive properties and essential molecular mechanisms involved in various diseases.

show abstract

Resveratrol supplementation improves inflammatory biomarkers in patients with nonalcoholic fatty liver disease

Cited by 274 publications

References 34 publications

Resveratrol Supplementation in Patients with Non-Alcoholic Fatty Liver Disease: Systematic Review and Meta-analysis

Resveratrol Supplementation in Patients with Non-Alcoholic Fatty Liver Disease: Systematic Review and Meta-analysis

Nonalcoholic Fatty Liver Disease, the Gut Microbiome, and Diet

Resveratrol: A miraculous natural compound for diseases treatment

Contact Info

Product

Resources

About